Vericel (VCEL) stock price is $40.33, down 0.63% on the day, as of Oct 21, 2026. It has a market cap of $2.07Bn and a P/E ratio of 85.49, and is classified in the Gene and Cell Therapy industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap2.07 Bn
P/E85.49
P/S6.76
Div. Yield0.00
Revenue Growth (1y) (Qtr)22.48
Add ratio to table…
About
Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn markets. The company develops manufactures and markets cell therapy and specialty biologic products that combine biological innovation with medical technology. Its portfolio includes two FDA approved autologous cell therapies MACI and Epicel and an exclusive license for the North American rights to NexoBrid a topical enzymatic product for burn care. Vericel operates from…
Vericel Corporation is a leading provider of advanced therapies for the sports medicine and severe burn markets. The company develops manufactures and markets cell therapy and specialty biologic products that combine biological innovation with medical technology. Its portfolio includes two FDA approved autologous cell therapies MACI and Epicel and an exclusive license for the North American rights to NexoBrid a topical enzymatic product for burn care. Vericel operates from facilities in Massachusetts and relies on a partnership with MediWound for the production of NexoBrid. The company’s manufacturing process for MACI and Epicel occurs in a cGMP compliant facility in Cambridge Massachusetts with plans to shift primary production to a newly validated site in Burlington Massachusetts. MACI is an autologous cellularized scaffold product used to repair symptomatic full thickness cartilage defects of the knee with or without bone involvement. Epicel is a permanent skin replacement indicated for adult and pediatric patients with deep dermal or full thickness burns covering at least thirty percent of total body surface area. NexoBrid is a lyophilized proteolytic enzyme preparation that removes eschar while preserving viable tissue in patients with deep partial thickness or full thickness thermal burns. Together these products address significant unmet medical needs in orthopedic and burn care specialties.
Vericel generates revenue primarily through the sale of its therapeutic products to hospitals surgery centers and specialized burn clinics. The company sells the MACI implant along with companion biopsy kits used to harvest patient cartilage and the MACI Arthro instruments that enable arthroscopic delivery of the implant. Epicel is sold as a cultured epidermal autograft for large surface area burns and NexoBrid is distributed through specialty distributors who resell the product to health care providers. In addition Vericel receives fees from its contract manufacturing arrangements and from licensing agreements that support the commercialization of its therapies. Revenue is also derived from the sale of ancillary items such as sterilization kits and patient support services that accompany the implantation procedures. The majority of sales are reimbursed by private insurance companies Medicare and Medicaid which have established coverage policies for MACI Epicel and NexoBrid in many jurisdictions. Vericel monitors payer policies closely and works with health care providers to obtain prior authorizations when needed to ensure timely access to its products. The company’s commercial organization includes a dedicated sales force for orthopedic products and a separate burn care team that promotes Epicel and NexoBrid to clinical specialists. Seasonal patterns affect MACI sales with higher volumes typically observed in the fourth quarter due to insurance deductible cycles and patient rehabilitation timing.
Vericel holds a distinctive position in the regenerative medicine field as one of the few companies with FDA approved autologous cell therapies for knee cartilage repair and severe burn treatment. Its main competitors in the cartilage repair space include manufacturers of microfracture augmentations such as Arthrex and Stryker providers of osteochondral allografts like Zimmer Biomet and emerging biologic products such as those from Histogenics and CartiHeal. In the burn care arena Vericel competes with traditional surgical excision and other enzymatic debridement agents like Santyl while its products Epicel and NexoBrid offer unique benefits of tissue preservation and reduced grafting needs. Competitive advantages stem from its proprietary manufacturing processes its exclusive license for NexoBrid in North America and its established reimbursement policies with major private and public payers. The company’s intellectual property portfolio includes patents covering chondrocyte identification methods and collagen membrane compositions that provide protection for its core technologies. These patents are scheduled to expire between 2028 and 2043 offering a medium term barrier to generic entry. Additionally Vericel benefits from twelve years of data exclusivity for MACI which extends to December 2028 limiting the ability of competitors to rely on its clinical data. The firm’s focus on niche indications such as large burn defects and articular cartilage lesions allows it to avoid direct competition with larger diversified medical device companies. Strong relationships with key opinion leaders in orthopedics and burn surgery further reinforce its market position and support adoption of new techniques such as arthroscopic MACI delivery.
Vericel serves a diverse customer base that includes hospitals ambulatory surgery centers and specialized burn clinics across the United States. The company distributes MACI through specialty pharmacy partners such as Orsini Pharmaceutical Services and AllCare Plus Pharmacy and supplies the product to military facilities via a distributor DMS Pharmaceutical Group. Epicel and NexoBrid are sold directly to hospitals and burn centers and through specialty distributors that reach health care providers nationwide. In addition Vericel works with academic medical centers and research institutions that conduct clinical trials and provide real world evidence on the efficacy of its therapies. The burn care team engages with multidisciplinary groups that include surgeons nurses and therapists who are involved in the acute management of severe burn injuries. Orthopedic surgeons who perform high volumes of knee cartilage procedures represent a core segment of the MACI customer base and are targeted through educational programs and peer to peer outreach. Specific customer names disclosed in public filings include Orsini Pharmaceutical Services AllCare Plus Pharmacy DMS Pharmaceutical Group and several large health systems such as Mayo Clinic Cleveland Clinic and Kaiser Permanente where the company has reported product usage. Geographic expansion efforts are underway with plans to seek regulatory approval for MACI in the United Kingdom and to explore opportunities in other international markets where burn care and sports medicine needs are growing.
Sector:HealthcareSector rationaleVericel develops, manufactures, and markets FDA-approved cell therapies and biologic products such as MACI, Epicel, and NexoBrid for sports medicine and burn care. Its revenue is derived from selling these therapeutic products to hospitals, surgery centers, and specialized burn clinics, which falls squarely within the Pharmaceuticals, Biotechnology, and Medical Devices industries of the Healthcare sector.Industries:Gene and Cell TherapyGene and Cell TherapyPrimaryVericel's core business is the development and commercialization of autologous cell therapies, specifically MACI for cartilage repair and Epicel for severe burns. These products involve the modification and application of a patient's own cells, which aligns directly with the Gene and Cell Therapy classification.Medical DevicesMedical DevicesSecondaryThe company sells medical technology and instruments used for the delivery of its therapies, specifically the MACI Arthro instruments used for arthroscopic delivery of the implant.Classified using BQ-MICSCIK: 0000887359
Bull & bear
Investment Thesis
▲ Bull case
Vericel Corporation is positioned for sustained high-growth momentum driven by the commercial scalability of its MACI franchise, where the expanded sales force has already demonstrated record biopsy and implant growth in new and legacy territories, with leading indicators showing higher biopsy conversion rates among MACI Arthro-trained surgeons who now account for over half of implants; this structural shift toward less invasive, arthroscopically delivered procedures expands the addressable patient population beyond traditional femoral condyle defects to include smaller lesions and patellar applications, creating a multi-year runway for volume growth that management has not fully priced into guidance, as they explicitly state they are not assuming acceleration in the second half despite strong Q1 biopsy momentum and a particularly strong Q4 2025 biopsy trend that is expected to convert through Q2 and beyond, implying potential upside to MACI revenue if conversion rates continue to rise as seen in early Arthro data showing reduced pain, faster weight-bearing, and improved range of motion—clinical outcomes that could unlock broader reimbursement and surgeon adoption beyond current estimates.
The FDA approval for MACI commercial manufacturing at the new facility removes a critical supply chain constraint and enables international expansion, with management confirming they remain on track for a U.K. marketing application submission later this year and a potential 2027 launch, supported by a positive NICE opinion and significant surgeon awareness in a market where restorative cartilage repair options are severely limited; this represents a material, low-cost avenue for geographic diversification that is not yet reflected in current valuation multiples, as the U.K. and broader European market could contribute meaningfully to long-term revenue without requiring significant additional sales infrastructure, given the concentrated nature of orthopedic centers of excellence and the product’s established clinical pedigree in the region prior to its prior withdrawal.
The BARDA contract for NexoBrid, valued at up to $197 million over a decade, includes not only the initial $10 million procurement allocation but also vendor-managed inventory (VMI) services and development funding for a blast trauma indication, which, if successful, could unlock additional procurement phases and expand NexoBrid’s utility beyond routine burn care into mass casualty and military applications; management highlighted that nearly two-thirds of the contract value flows to Vericel through revenue or cost offsets, and the VMI model is designed to scale with stockpile growth—currently at ~3,000 units with a planned ramp-up to 8,000—implying that NexoBrid revenue could exceed the $5–6 million H2 2026 expectation significantly if BARDA exercises optional awards, particularly as the company begins to see broadening of ordering centers and growing order frequency, signaling early traction in shifting standard of care from surgical to enzymatic eschar removal in U.S. burn centers.
Epicel’s strength is being driven by improved biopsy-to-graft conversion rates rather than just biopsy volume, reflecting a refined commercial execution model where the sales force, supported by clinical teams, is effectively identifying and treating appropriate patients—a shift that indicates higher-quality demand and better patient selection, which could lead to more predictable, sustainable revenue growth and stronger payer relationships over time, as opposed to episodic volume spikes; this underlying improvement in commercial effectiveness, combined with Epicel’s status as a humanitarian use device with limited competition and no generic threat, provides a durable, high-margin foundation for the Burn Care franchise that is less vulnerable to procedural volume headwinds affecting broader orthopedics.
Vericel Corporation is positioned for sustained high-growth momentum driven by the commercial scalability of its MACI franchise, where the expanded sales force has already demonstrated record biopsy and implant growth in new and legacy territories, with leading indicators showing higher biopsy conversion rates among MACI Arthro-trained surgeons who now account for over half of implants; this structural shift toward less invasive, arthroscopically delivered procedures expands the addressable patient population beyond traditional femoral condyle defects to include smaller lesions and patellar applications, creating a multi-year runway for volume growth that management has not fully priced into guidance, as they explicitly state they are not assuming acceleration in the second half despite strong Q1 biopsy momentum and a particularly strong Q4 2025 biopsy trend that is expected to convert through Q2 and beyond, implying potential upside to MACI revenue if conversion rates continue to rise as seen in early Arthro data showing reduced pain, faster weight-bearing, and improved range of motion—clinical outcomes that could unlock broader reimbursement and surgeon adoption beyond current estimates.
The FDA approval for MACI commercial manufacturing at the new facility removes a critical supply chain constraint and enables international expansion, with management confirming they remain on track for a U.K. marketing application submission later this year and a potential 2027 launch, supported by a positive NICE opinion and significant surgeon awareness in a market where restorative cartilage repair options are severely limited; this represents a material, low-cost avenue for geographic diversification that is not yet reflected in current valuation multiples, as the U.K. and broader European market could contribute meaningfully to long-term revenue without requiring significant additional sales infrastructure, given the concentrated nature of orthopedic centers of excellence and the product’s established clinical pedigree in the region prior to its prior withdrawal.
The BARDA contract for NexoBrid, valued at up to $197 million over a decade, includes not only the initial $10 million procurement allocation but also vendor-managed inventory (VMI) services and development funding for a blast trauma indication, which, if successful, could unlock additional procurement phases and expand NexoBrid’s utility beyond routine burn care into mass casualty and military applications; management highlighted that nearly two-thirds of the contract value flows to Vericel through revenue or cost offsets, and the VMI model is designed to scale with stockpile growth—currently at ~3,000 units with a planned ramp-up to 8,000—implying that NexoBrid revenue could exceed the $5–6 million H2 2026 expectation significantly if BARDA exercises optional awards, particularly as the company begins to see broadening of ordering centers and growing order frequency, signaling early traction in shifting standard of care from surgical to enzymatic eschar removal in U.S. burn centers.
Epicel’s strength is being driven by improved biopsy-to-graft conversion rates rather than just biopsy volume, reflecting a refined commercial execution model where the sales force, supported by clinical teams, is effectively identifying and treating appropriate patients—a shift that indicates higher-quality demand and better patient selection, which could lead to more predictable, sustainable revenue growth and stronger payer relationships over time, as opposed to episodic volume spikes; this underlying improvement in commercial effectiveness, combined with Epicel’s status as a humanitarian use device with limited competition and no generic threat, provides a durable, high-margin foundation for the Burn Care franchise that is less vulnerable to procedural volume headwinds affecting broader orthopedics.
Vericel Corporation’s guidance assumes no procedural volume headwinds from broader orthopedic market pressures, including ACA subsidy expiration and access-related delays, despite explicit acknowledgment from management that they are monitoring the environment and have not seen signals yet—this omission represents a material risk, as MACI’s growth is inherently tied to elective orthopedic procedure volumes, which are sensitive to macroeconomic factors, insurance policy changes, and patient discretionary spending; if broader orthopedic volumes begin to decline as feared by analysts, MACI’s biopsy and implant growth could decelerate rapidly, especially since the company’s guidance framework relies on maintaining recent biopsy acceleration trends without building in any downside scenario, leaving the stock vulnerable to a sharp repricing if Q2 or H2 2026 shows any signs of procedure softening that contradicts management’s current optimism.
The BARDA contract, while significant in headline value, carries substantial execution risk and timing uncertainty, as the $197 million potential is contingent on multiple optional awards over a decade, with the initial $10 million procurement allocation only partially realized in 2026 ($5–6 million H2), and the remainder dependent on BARDA’s annual appropriations, political priorities, and successful completion of milestones like the blast trauma indication proof of concept—management admitted they will provide “potentially more guidance” on optional awards as they go through the year, signaling that near-term revenue visibility beyond the initial allocation is low, and the market may be overestimating the immediate and scalable impact of this contract, especially given NexoBrid’s current low base ($1.1 million Q1 revenue) and the long sales cycle associated with changing standard of care in burn centers, which requires clinical education, protocol changes, and reimbursement alignment—factors that could delay adoption far beyond management’s expectations.
MACI Arthro’s current penetration—over half of implants coming from trained surgeons—may reflect a temporary surge from recent training efforts rather than sustainable, organic adoption, as the gap in biopsy and implant growth rates between Arthro-trained and non-trained surgeons is narrowing despite the trained base expanding, suggesting that the initial enthusiasm is diffusing and the procedural advantage may not be translating into durable, differentiated outcomes at scale; while early case series show promising pain reduction and faster weight-bearing, these are investigator-led, non-randomized studies, and broader clinical validation through the MACI clinical outcomes registry remains pending, meaning that without robust, peer-reviewed data demonstrating superior long-term outcomes, reimbursement payers may resist wider adoption, limiting Arthro’s ability to drive premium pricing or expand beyond niche femoral condyle defects into higher-volume anatomical sites like the patella, where instruments are not yet optimized and open procedures remain standard.
The company’s reliance on Epicel’s improved biopsy conversion rates as a driver of Burn Care growth introduces vulnerability to shifts in patient acuity or referral patterns, as Epicel is indicated only for severe burns requiring permanent skin replacement—a narrow, volatile patient pool that fluctuates based on seasonal burn incidents, trauma center admissions, and referral network stability; although Epicel revenue was strong in Q1 due to higher treatment rates, this metric is highly dependent on commercial execution and clinical judgment, which can vary quarter-to-quarter, and there is no evidence of systemic improvement in underlying burn incidence or referral behavior—meaning the recent strength could be episodic rather than structural, and any downturn in severe burn volume or conversion efficiency would directly impact a franchise that contributes meaningfully to total revenue and lacks diversification beyond Epicel and NexoBrid, the latter of which remains immature and unproven at scale.
Vericel Corporation’s guidance assumes no procedural volume headwinds from broader orthopedic market pressures, including ACA subsidy expiration and access-related delays, despite explicit acknowledgment from management that they are monitoring the environment and have not seen signals yet—this omission represents a material risk, as MACI’s growth is inherently tied to elective orthopedic procedure volumes, which are sensitive to macroeconomic factors, insurance policy changes, and patient discretionary spending; if broader orthopedic volumes begin to decline as feared by analysts, MACI’s biopsy and implant growth could decelerate rapidly, especially since the company’s guidance framework relies on maintaining recent biopsy acceleration trends without building in any downside scenario, leaving the stock vulnerable to a sharp repricing if Q2 or H2 2026 shows any signs of procedure softening that contradicts management’s current optimism.
The BARDA contract, while significant in headline value, carries substantial execution risk and timing uncertainty, as the $197 million potential is contingent on multiple optional awards over a decade, with the initial $10 million procurement allocation only partially realized in 2026 ($5–6 million H2), and the remainder dependent on BARDA’s annual appropriations, political priorities, and successful completion of milestones like the blast trauma indication proof of concept—management admitted they will provide “potentially more guidance” on optional awards as they go through the year, signaling that near-term revenue visibility beyond the initial allocation is low, and the market may be overestimating the immediate and scalable impact of this contract, especially given NexoBrid’s current low base ($1.1 million Q1 revenue) and the long sales cycle associated with changing standard of care in burn centers, which requires clinical education, protocol changes, and reimbursement alignment—factors that could delay adoption far beyond management’s expectations.
MACI Arthro’s current penetration—over half of implants coming from trained surgeons—may reflect a temporary surge from recent training efforts rather than sustainable, organic adoption, as the gap in biopsy and implant growth rates between Arthro-trained and non-trained surgeons is narrowing despite the trained base expanding, suggesting that the initial enthusiasm is diffusing and the procedural advantage may not be translating into durable, differentiated outcomes at scale; while early case series show promising pain reduction and faster weight-bearing, these are investigator-led, non-randomized studies, and broader clinical validation through the MACI clinical outcomes registry remains pending, meaning that without robust, peer-reviewed data demonstrating superior long-term outcomes, reimbursement payers may resist wider adoption, limiting Arthro’s ability to drive premium pricing or expand beyond niche femoral condyle defects into higher-volume anatomical sites like the patella, where instruments are not yet optimized and open procedures remain standard.
The company’s reliance on Epicel’s improved biopsy conversion rates as a driver of Burn Care growth introduces vulnerability to shifts in patient acuity or referral patterns, as Epicel is indicated only for severe burns requiring permanent skin replacement—a narrow, volatile patient pool that fluctuates based on seasonal burn incidents, trauma center admissions, and referral network stability; although Epicel revenue was strong in Q1 due to higher treatment rates, this metric is highly dependent on commercial execution and clinical judgment, which can vary quarter-to-quarter, and there is no evidence of systemic improvement in underlying burn incidence or referral behavior—meaning the recent strength could be episodic rather than structural, and any downturn in severe burn volume or conversion efficiency would directly impact a franchise that contributes meaningfully to total revenue and lacks diversification beyond Epicel and NexoBrid, the latter of which remains immature and unproven at scale.